19319511

Source:http://linkedlifedata.com/resource/pubmed/id/19319511

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0031444, umls-concept:C0231242, umls-concept:C1521970
pubmed:issue	8
pubmed:dateCreated	2009-7-24
pubmed:abstractText	Anticoagulation therapy with coumarins necessitates a strict individualization of dosing. Whereas the impacts of the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) polymorphisms on warfarin dosing are clearly established, the role of these genetic variants on dosing and the safe use of phenprocoumon are less well investigated and, to a certain degree, controversial.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/1256165
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants, http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases, http://linkedlifedata.com/resource/pubmed/chemical/CYP2C9 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/CYP3A5 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A, http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases, http://linkedlifedata.com/resource/pubmed/chemical/Phenprocoumon, http://linkedlifedata.com/resource/pubmed/chemical/vitamin K epoxidase
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1432-1041
pubmed:author	pubmed-author:EschenhagenTT, pubmed-author:GroschAA, pubmed-author:LestinH GHG, pubmed-author:RaoRR, pubmed-author:WernerDD, pubmed-author:WernerUU, pubmed-author:WuerfelAA
pubmed:issnType	Electronic
pubmed:volume	65
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	783-8
pubmed:meshHeading	pubmed-meshheading:19319511-Administration, Oral, pubmed-meshheading:19319511-Aged, pubmed-meshheading:19319511-Aged, 80 and over, pubmed-meshheading:19319511-Anticoagulants, pubmed-meshheading:19319511-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:19319511-Cytochrome P-450 CYP3A, pubmed-meshheading:19319511-Dose-Response Relationship, Drug, pubmed-meshheading:19319511-Drug Administration Schedule, pubmed-meshheading:19319511-European Continental Ancestry Group, pubmed-meshheading:19319511-Female, pubmed-meshheading:19319511-Gene Frequency, pubmed-meshheading:19319511-Genotype, pubmed-meshheading:19319511-Germany, pubmed-meshheading:19319511-Haplotypes, pubmed-meshheading:19319511-Humans, pubmed-meshheading:19319511-Male, pubmed-meshheading:19319511-Middle Aged, pubmed-meshheading:19319511-Mixed Function Oxygenases, pubmed-meshheading:19319511-Phenprocoumon, pubmed-meshheading:19319511-Polymorphism, Genetic
pubmed:year	2009
pubmed:articleTitle	Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.
pubmed:affiliation	Department of Cardiology/Angiology, Protestant Community Hospital, Ludwigslust, Germany.
pubmed:publicationType	Journal Article, Comparative Study